How Practical Is FDA’s HCP Approach in DCTs?
The FDA’s latest guidance on Decentralized Clinical Trials (DCTs) marks a pivotal shift in the clinical research landscape. This...
FDA Needs To Release ClinicalTrials.gov Guidance Now
The 2024 Clinical Trials Transformation Initiative (CTTI) report, drawing on a broad spectrum of responses from diverse stakeholders in...
Master Protocols: FDA New Flexible Approach in Cancer Trials
Master Protocols (MPs) mark a significant evolution in the realm of clinical research, especially notable in oncology. These protocols,...
A Great Divide: Sponsors Clash With FDA on Trial Data Excess
A new study, conducted collaboratively by the Tufts Center for the Study of Drug Development (Tufts CSDD), the FDA,...
FDA Unveils Groundbreaking Rare Disease Guidance Document
In a landmark move, the U.S. Food and Drug Administration (FDA) has released a detailed guidance document titled “Rare...
Shattering Myths FDA New Era of Diverse Healthcare Solutions
In an era marked by rapid advancements in healthcare, the importance of inclusivity and innovation in clinical trials and...
Sunshine Act Compliance: A Better Empowerment for Life Science Companies
The origins of the Sunshine Act can be traced back to growing calls for transparency in healthcare and Life...
How To Safeguard Your Clinical Trial In The Era Of AI
The AI Bill of Rights, released by the White House, offers a comprehensive guide to ensuring AI’s ethical and...
Choosing the Right FDA Regulatory Law Firm for Acquisition
Navigating the complex waters of acquiring an FDA-regulated company requires expertise beyond typical acquisition strategies. Given the unique regulatory...
Clinical Trial Patient Engagement and Experience Data: Why It’s Vital
A significant shift towards prioritizing clinical trial patient engagement (PE) and patient experience data (PXD) is palpable in clinical...